A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors

Trial Profile

A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Lanreotide (Primary) ; Octreotide
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 14 Jul 2017 to 14 Dec 2017.
    • 28 Aug 2017 Planned primary completion date changed from 14 Jul 2017 to 14 Dec 2017.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top